These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23312488)

  • 21. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
    Stute P
    Arch Gynecol Obstet; 2013 Dec; 288(6):1199-201. PubMed ID: 24178484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women.
    Suwanvesh N; Manonai J; Sophonsritsuk A; Cherdshewasart W
    Menopause; 2017 Feb; 24(2):210-215. PubMed ID: 27749740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recognizing and treating urogenital atrophy in postmenopausal women.
    Goldstein I
    J Womens Health (Larchmt); 2010 Mar; 19(3):425-32. PubMed ID: 20156082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets.
    Panay N; Maamari R
    Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
    Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
    Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should I stay for local hormone therapy or should I go for radiofrequency to treat vulvovaginal atrophy? A patient preference trial.
    Dell'Utri CM; Manzoni E; Bonfanti I; Marrocco F; Barbara G; Pifarotti P; Chiaffarino F
    Menopause; 2024 Sep; 31(9):801-808. PubMed ID: 38954491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of nettle vaginal cream on subjective symptoms of vaginal atrophy in postmenopausal women.
    Karimi FZ; Nazari N; Rakhshandeh H; Mazloum SR
    Eur J Obstet Gynecol Reprod Biol; 2023 Jun; 285():41-45. PubMed ID: 37044017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy.
    Parsons A; Merritt D; Rosen A; Heath H; Siddhanti S; Plouffe L;
    Obstet Gynecol; 2003 Feb; 101(2):346-52. PubMed ID: 12576260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial.
    Paraiso MFR; Ferrando CA; Sokol ER; Rardin CR; Matthews CA; Karram MM; Iglesia CB
    Menopause; 2020 Jan; 27(1):50-56. PubMed ID: 31574047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaginal estrogens for the treatment of dyspareunia.
    Krychman ML
    J Sex Med; 2011 Mar; 8(3):666-74. PubMed ID: 21091878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What should guide our patient management of vulvovaginal atrophy?
    Shapiro M
    Climacteric; 2019 Feb; 22(1):38-43. PubMed ID: 30452294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women.
    Tersigni C; Di Simone N; Tempestilli E; Cianfrini F; Russo R; Moruzzi MC; Amar ID; Fiorelli A; Scambia G; Villa P
    J Obstet Gynaecol; 2015; 35(8):835-8. PubMed ID: 25968636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women.
    Goldstein I; Alexander JL
    J Sex Med; 2005 Sep; 2 Suppl 3():154-65. PubMed ID: 16422792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause.
    Agrawal S; LaPier Z; Nagpal S; Oot A; Friedman S; Hade EM; Nachtigall L; Brucker BM; Escobar C
    Menopause; 2024 Sep; 31(9):750-755. PubMed ID: 39042017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overview of chronic vaginal atrophy and options for symptom management.
    Woods NF
    Nurs Womens Health; 2012 Dec; 16(6):482-93; quiz 494. PubMed ID: 23253575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
    Matarazzo MG; Caruso S; Giunta G; Valenti G; Sarpietro G; Cianci A
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():75-79. PubMed ID: 29367168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of local estrogen therapy for urogenital atrophy.
    Archer DF
    Menopause; 2010; 17(1):194-203. PubMed ID: 19602990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen and its effect on vaginal atrophy in post-menopausal women.
    Kelley C
    Urol Nurs; 2007 Feb; 27(1):40-5. PubMed ID: 17390926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.